ADIA Nutrition Inc. Provides Shareholder Update on Acquisition of Biolete Inc. and Financial Position
ADIA Nutrition Inc. Provides Shareholder Update on Acquisition of Biolete Inc. and Financial Position
Winter Park, Florida--(Newsfile Corp. - August 27, 2024) - ADIA Nutrition Inc. (OTC Pink: ADIA) is pleased to provide a shareholder update regarding its recent acquisition of Biolete Inc. and its financial position.
佛羅里達溫特帕克--(新聞稿Corp. - 2024年8月27日) - ADIA營養公司(OTC粉紅色: ADIA)高興地向股東們提供有關其最近收購Biolete公司及其財務狀況的更新。
As part of the acquisition, ADIA Nutrition has acquired not only the Biolete corporation and its trademark but also its current customer base, which has been generating revenue for Biolete. Additionally, ADIA Nutrition has taken possession of the Biolete Coffee inventory, from both of Biolete's former warehouses.
作爲收購的一部分,ADIA營養不僅收購了Biolete公司及其商標,還收購了其目前的客戶群體,這爲Biolete帶來了收入。此外,ADIA營養已經取得了Biolete咖啡的庫存,來自Biolete的兩個原倉庫。
The global high-protein coffee market was valued at approximately USD 1.56 billion in 2021 and is projected to reach USD 2.64 billion by 2029. Similarly, the global mushroom coffee market was valued at USD 2.71 billion in 2022 and is expected to grow at a CAGR of 5.5% from 2023 to 2030, reaching approximately USD 4.12 billion by 2030.
2021年全球高蛋白咖啡市場價值約爲15600萬美元,在2029年預計將達到26400萬美元。同樣,2022年全球蘑菇咖啡市場價值爲27100萬美元,預計從2023年到2030年將以5.5%的複合年增長率增長,到2030年將達到約41200萬美元。
The acquisition of Biolete's customer base and inventory strengthens ADIA Nutrition's position in the market and provides a solid foundation for growth.
收購Biolete的客戶群體和庫存,增強了ADIA營養在市場中的地位,併爲其增長提供了堅實的基礎。
This includes ADIA's offering of Biolete coffee across various platforms including Amazon. The company is confident in its ability to leverage these assets to drive revenue and enhance shareholder value.
這包括ADIA在亞馬遜等多個平台上提供Biolete咖啡。公司對利用這些資產推動營收增長和提升股東價值充滿信心。
ADIA Nutrition would also like to clarify that ADIA has no debt for deferred salaries, convertible notes, or any other toxic debt. ADIA's only debt is and will be draws from its 6% Annum $500,000 line of credit.
ADIA營養還想澄清的是,ADIA沒有遞延薪金、可轉換票據或任何其他有毒債務。ADIA唯一的債務是從其年利率爲6%的50萬美元授信額度中提取的款項。
ADIA does not require additional funding beyond the $500,000 line of credit provided by its CEO, Larry Powalisz. This line of credit should be more than sufficient to support the opening of ADIA Nutrition's first clinic for aHSCT for MS and to support the company's supplement division. At this time the company is well-positioned to execute its business plan without the need for additional capital from ADIA's Reg. A.
ADIA不需要其他資金,除了由其CEO Larry Powalisz提供的50萬美元信用額度。這個信用額度足以支持ADIA營養的第一個MS幹細胞治療診所的開設,並支持公司的營養保健品部門。目前,該公司已經做好了在不需要ADIA Reg. A額外資本的情況下執行其業務計劃的準備。
"We are excited about the acquisition of Biolete and the opportunities it presents for ADIA Nutrition," said Larry Powalisz, CEO of ADIA Nutrition Inc. "The acquisition of the customer base and inventory, along with the line of credit provided by myself, positions us for success in the coming months. We are confident in our ability to expedite our business plan and not only create value for our shareholders, but also help MS Patients faster than originally anticipated."
"我們對收購Biolete和其爲ADIA營養帶來的機遇感到興奮," ADIA營養公司的CEO Larry Powalisz說道。"通過收購客戶群體和庫存,再加上我個人提供的信用額度,我們在未來幾個月中在成功方面將取得有力的地位。我們對加快執行我們的業務計劃充滿信心,不僅爲股東創造價值,還將幫助更快地幫助多發性硬化症患者。"
For media inquiries or further information, please contact Larry Powalisz at ceo@adiamed.com or 321-788-0850.
有關媒體查詢或更多信息,請通過ceo@adiamed.com或321-788-0850聯繫Larry Powalisz。
About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division specializing in Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments for Multiple Sclerosis (MS). Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.
關於ADIA營養公司:
Adia營養公司是一家公開交易公司(OTC Pink:ADIA),致力於改革醫療保健和補充劑。公司專注於創新和質量,已建立了兩個關鍵部門:提供高質量有機補充劑的補充部門和專門從事多發性硬化症(MS)的自體造血幹細胞移植(aHSCT)治療的醫療部門。通過這些部門,Adia營養公司致力於通過滿足營養需求和突破性的醫療治療措施來賦予個人更好的生活。
Website:
網站:
Website:
網站:
Website:
網站:
Website:
網站:
Twitter (X): @ADIA_Nutrition
Twitter(X):@ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
安全港:本新聞稿包含根據1933年證券法第27A條和1934年證券交易法第21E條的前瞻性聲明。這些前瞻性聲明基於管理層的當前計劃和期望,並受到一些不確定性和風險的影響,這些風險和不確定性可能會顯著影響公司的當前計劃和期望,以及未來的經營業績和財務狀況。關於公司業務前景以及可能影響公司業務前景並導致實際結果與前瞻性聲明描述的結果有很大不同的風險和因素的更詳細列表,可以在公司向證券交易委員會和OTC Markets,Inc. OTC Disclosure and News Service提交的報告和其他文件中找到。公司不承擔公開更新或修訂任何前瞻性聲明的義務,因爲有新信息,未來事件或其他情況。
譯文內容由第三人軟體翻譯。